Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.

The Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase first identified as the product of a gene rearrangement in Anaplastic Large Cell Lymphoma. ALK has subsequently been found to be rearranged, mutated, or amplified in a further series of tumours including neuroblastoma, and Non-Small Cell Lung Cancer. There is strong preclinical evidence that ALK is a driving force for oncogenesis in these cases, and that inhibition of ALK kinase activity results in anti-tumoural efficacy. These observations have sparked the development of small molecule kinase inhibitors, the most advanced of which is currently in clinical testing and which has shown promising preliminary activity in the subset of lung cancer patients whose tumours harbour activated ALK. In this review, we describe the various oncogenic forms of ALK, relevant clinical settings, and give a detailed overview of current drug discovery efforts in the field.

[1]  K. Sango,et al.  Pleiotrophin induces neurite outgrowth and up-regulates growth-associated protein (GAP)-43 mRNA through the ALK/GSK3β/β-catenin signaling in developing mouse neurons , 2010, Neuroscience Research.

[2]  E. Campo,et al.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. , 1999, Blood.

[3]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[4]  H. Mano Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer , 2008, Cancer science.

[5]  L. Scapozza,et al.  An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. , 2005, Haematologica.

[6]  C. Naeve,et al.  ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) , 1997, Oncogene.

[7]  A. Iafrate,et al.  Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. D. Dal Cin,et al.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. , 2000, The American journal of pathology.

[9]  B. Ruggeri,et al.  Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. , 2006, Blood.

[10]  L. Shewchuk,et al.  Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. , 2009, Bioorganic & medicinal chemistry letters.

[11]  S. Mori,et al.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. , 1995, Leukemia.

[12]  A. Aigner,et al.  Ribozyme‐targeting reveals the rate‐limiting role of pleiotrophin in glioblastoma , 2005, International journal of cancer.

[13]  A. Ghose,et al.  Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. , 2010, Bioorganic & medicinal chemistry.

[14]  H. Mano,et al.  EML4-ALK fusion in lung. , 2010, The American journal of pathology.

[15]  E. Campo,et al.  A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. , 2000, Cancer research.

[16]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[17]  H. Satoh,et al.  Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. , 1994, Oncogene.

[18]  Nathanael Gray,et al.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.

[19]  N. Brooijmans,et al.  Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies , 2009 .

[20]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Arakawa,et al.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.

[22]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[23]  K. Pulford,et al.  Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). , 2000, Blood.

[24]  M. Werner,et al.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.

[25]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[26]  T. Clackson,et al.  Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) , 2010 .

[27]  A. Cuneo,et al.  ALK -positive diffuse large B-cell lymphoma , 2011 .

[28]  P. Marynen,et al.  ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. , 2003, Blood.

[29]  Q. Zhan,et al.  Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma , 2007, Journal of Molecular Medicine.

[30]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[31]  E. Campo,et al.  Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells , 2004, Oncogene.

[32]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[33]  D. Wen,et al.  Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin* , 2001, The Journal of Biological Chemistry.

[34]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[35]  P. LoRusso,et al.  Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology , 2008, Expert opinion on investigational drugs.

[36]  L. Scapozza,et al.  Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. , 2006, Journal of medicinal chemistry.

[37]  J. Renauld,et al.  Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice , 2003, Oncogene.

[38]  S. Morris,et al.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. , 2000, Blood.

[39]  R. Palmer,et al.  Characterization of the expression of the ALK receptor tyrosine kinase in mice. , 2006, Gene expression patterns : GEP.

[40]  J. Chan,et al.  ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. , 2008, Blood.

[41]  A. Rosenwald,et al.  t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. , 1999, Blood.

[42]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[43]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[44]  K. Maclennan,et al.  Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase , 2003, Oncogene.

[45]  C. Powers,et al.  Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth* , 2002, The Journal of Biological Chemistry.

[46]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[47]  M. Ladanyi,et al.  Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. , 2001, The American journal of pathology.

[48]  G. R. Ott,et al.  Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. , 2010, Anti-cancer agents in medicinal chemistry.

[49]  J. Downing,et al.  ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. , 2003, Blood.

[50]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[51]  Sreenath V. Sharma,et al.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.

[52]  G. Inghirami,et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.

[53]  Rongshi Li,et al.  Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy , 2008, Medicinal research reviews.

[54]  L. Scapozza,et al.  Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy , 2005, Expert opinion on therapeutic targets.

[55]  Petr Znamenskiy,et al.  Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications , 2008, Neuropsychopharmacology.

[56]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[57]  L. Shun An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms , 2010 .

[58]  P. Włodarski,et al.  Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3 , 2005, Laboratory Investigation.

[59]  L. Scapozza,et al.  Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. , 2005, Biochemistry.

[60]  E. Campo,et al.  Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma , 2001, Laboratory Investigation.

[61]  A. Wellmann,et al.  Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. , 2005, Anticancer research.

[62]  P. Meltzer,et al.  Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. , 2011, Cancer research.

[63]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[64]  西村 勁一郎,et al.  Synthesis and Structure-Activity Relationships , 1998 .

[65]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[66]  C. Powers,et al.  Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types* , 2002, The Journal of Biological Chemistry.

[67]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[68]  R. Siebert,et al.  Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. , 2000, Blood.

[69]  M. Varella‐Garcia,et al.  ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[70]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[71]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[72]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Delsol,et al.  TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. , 2007, European journal of cancer.

[75]  K. Pulford,et al.  Expression of the ALK tyrosine kinase gene in neuroblastoma. , 2000, The American journal of pathology.

[76]  A. Ghose,et al.  ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. , 2009, Biochemistry.

[77]  R. Larson,et al.  Morphology in Ki‐1 (CD30)‐Positive Non Hodgkin's Lymphoma Is Correlated with Clinical Features and the Presence of a Unique Chromosomal Abnormality, t(2;5)(p23;q35) , 1990, The American journal of surgical pathology.

[78]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[79]  Florian Steinberg,et al.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. , 2009, Neoplasia.

[80]  W. Sanger,et al.  Expression of ALK1 and p80 in Inflammatory Myofibroblastic Tumor and Its Mesenchymal Mimics: A Study of 135 Cases , 2002, Modern Pathology.

[81]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  D. Govender,et al.  ALK protein expression in rhabdomyosarcomas. , 2002, Histopathology.

[83]  R. Taulli,et al.  Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. , 2006, Blood.

[84]  S. Nelson,et al.  Differential Induction of Glioblastoma Migration and Growth by Two Forms of Pleiotrophin* , 2005, Journal of Biological Chemistry.

[85]  P. Pandolfi,et al.  Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.

[86]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[87]  G. Tonini,et al.  Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. , 2009, Cancer research.

[88]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[89]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[90]  S. Morris,et al.  Translocations involving anaplastic lymphoma kinase (ALK) , 2001, Oncogene.

[91]  A. Look,et al.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy , 2009, Expert review of anticancer therapy.

[92]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[93]  Ming Zhou,et al.  Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.

[94]  S. Perkins,et al.  ALK1 and p80 Expression and Chromosomal Rearrangements Involving 2p23 in Inflammatory Myofibroblastic Tumor , 2001, Modern Pathology.

[95]  C. Griffin,et al.  Advances in Brief Recurrent Involvement of 2 p 23 in Inflammatory Myofibroblastic Tumors , 1999 .

[96]  C. Rampon,et al.  New neurons in the dentate gyrus are involved in the expression of enhanced long‐term memory following environmental enrichment , 2005, The European journal of neuroscience.

[97]  S. Pileri,et al.  The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues , 2009, Haematologica.

[98]  X. Wang,et al.  Nucleophosmin and human cancer. , 2006, Cancer detection and prevention.

[99]  W. Pao,et al.  EML4-ALK: honing in on a new target in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  R. Hen,et al.  Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants , 2003, Science.

[101]  S. Morris,et al.  The oncogenic fusion protein nucleophosmin–anaplastic lymphoma kinase (NPM–ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model , 2003, Oncogene.

[102]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[103]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[104]  A. Iafrate,et al.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.

[105]  Xiong-zeng Zhu,et al.  Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. , 2004, Human pathology.

[106]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[107]  E. Campo,et al.  EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.

[108]  H. Drexler,et al.  Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines , 2002, International journal of cancer.

[109]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[110]  Rongshi Li,et al.  Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. , 2006, Journal of medicinal chemistry.

[111]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[112]  S. Pileri,et al.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. , 1998, The American journal of pathology.

[113]  A. Höke,et al.  Pleiotrophin is a neurotrophic factor for spinal motor neurons , 2007, Proceedings of the National Academy of Sciences.

[114]  Francesca Demichelis,et al.  EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.

[115]  P. Sabbatini,et al.  GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers , 2009, Molecular Cancer Therapeutics.

[116]  K. Pulford,et al.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. , 1997, Blood.

[117]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[118]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[119]  F. Mertens,et al.  Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor , 2006, International journal of cancer.

[120]  J. Maris,et al.  Inhibition of ALK Signaling for Cancer Therapy , 2009, Clinical Cancer Research.

[121]  R. Malekzadeh,et al.  Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. , 2006, World journal of gastroenterology.